Oncology Biomarker Diagnostics

Linking molecular status to breakthroughs in cancer treatment

  • MolecularMD in the news
    MolecularMD in the news PORTLAND, OR-(Apr 9, 2013) - MolecularMD Corp. announced today that it has developed and clinically validated assays for determining LKB1 mutation and expression status in patient tumor samples. Click image for full story.
  • Next-Gen Sequencing at MolecularMD
    Next-Gen Sequencing at MolecularMD Our NGS Service offers comprehensive testing & support for drug development programs & clinical trials. Key features:
    • High multiplexing & sensitivity with minimal DNA/RNA
    • Commercial cancer panels & custom assays
    • Multiple sample types: FFPE, blood, plasma, bone marrow
  • Molecular Monitoring of Chronic Myeloid Leukemia
    Molecular Monitoring of Chronic Myeloid Leukemia Personalized medicine is rapidly developing a purposeful niche in the field of oncology. Monitoring the activity of the oncogenic fusion gene BCR–ABL1 in chronic myeloid leukemia (CML) is a good example of individualizing CML treatment for patients using patient-specific genetic information. Click image for full article.
  • Companion Diagnostics Partner
    Companion Diagnostics Partner MolecularMD strives to accelerate the pace of targeted therapy development to improve outcomes for cancer patients. We work collaboratively with our pharma partners to establish and maintain critical project timelines; we appreciate the importance of simultaneous CDx submission to successful registration of the therapeutic.
  • Our Mission
    Our Mission MolecularMD provides innovative and reliable molecular diagnostic solutions that improve and advance personalized medicine for cancer patients.
  • Custom Assay Design
    Custom Assay Design Our development capabilities include custom assay design based on partner preferences and practicalities related to the biomarker(s) being evaluated. We remain platform agnostic, continuously evaluating new technology and instrumentation with the goal of providing the current platform options to meet the scope and data requirements our partners and regulatory agencies demand.
  • Global Clinical Trials Support
    Global Clinical Trials Support MolecularMD has supported numerous international Phase 3 trials, and offers trusted global logistics support coordinated by a dedicated team of Clinical Trial Project Managers. This team applies its expertise and commitment to manage the global logistics of sample management.
  • Assay Development, Commitment to Quality
    Assay Development, Commitment to Quality Our assays undergo rigorous validations following the specific regulatory guidelines set by AMP, CLIA/CAP, and the FDA. Assay conditions are optimized to achieve the highest degree of accuracy, specificity, sensitivity, reproducibility, and efficiency. Each test is developed with appropriate controls that establish, monitor and guarantee high quality data each and every run.
  • MolecularMD in the news
  • Next-Gen Sequencing at MolecularMD
  • Molecular Monitoring of Chronic Myeloid Leukemia
  • Companion Diagnostics Partner
  • Our Mission
  • Custom Assay Design
  • Global Clinical Trials Support
  • Assay Development, Commitment to Quality
 

MolecularMD provides innovative and reliable molecular diagnostics products and services to support clinical development, regulatory approval, and commercialization of targeted cancer therapies.

Using both gold-standard and cutting-edge platforms, we design sensitive, specific, standardized assays that provide robust, reproducible results in an expeditious manner appropriate for decision-making by clinical investigators, sponsors, community physicians and patients.

At MolecularMD we are committed to accelerating the pace of targeted therapy development and personalizing medicine for cancer patients.